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Summary
The binding of nonspecific DNA to the C-terminal
negative regulatory domain (CTD) of p53 modulates
its activity. The CTD is a natively unfolded region,
which is subject to acetylation and phosphorylation
at several residues as part of control. To measure the
effect of covalent modification on binding to DNA, we
synthesized a series of fluorescein-labeled CTD pep-
tides with single and multiple acetylations at lysine
residues that we had identified by NMR as making
contact with DNA, and developed an analytical ultra-
centrifugation method to study their binding to DNA.
Binding depended on ionic strength, indicating an
electrostatic contribution. Monoacetylation weakened
DNA binding at physiological ionic strength 2- to
3-fold, diacetylations resulted in further 2- to 3-fold
decrease in the affinity, and tri- and tetraacetylations
rendered DNA binding undetectable. Phosphorylation
at S392 did not affect DNA binding. NMR spectros-
copy showed binding to DNA did not induce signifi-
cant structure into CTD, apart possibly from local he-
lix formation.
Introduction
The tumor suppressor protein p53 is a transcription
factor that responds to oncogenic stress by inducing
cell cycle arrest or apoptosis (Vogelstein et al., 2000;
Vousden and Lu, 2002). Each chain of 393 amino acids
is comprised of several functional domains: the N-ter-
minal transactivation domain (residues 1–60) (Fields
and Jang, 1990), the proline-rich regulatory domain
(residues 64–92) (Muller-Tiemann et al., 1998; Walker
and Levine, 1996), the DNA binding core domain (resi-
dues 94–312) (Cho et al., 1994), the tetramerization do-
main (residues 324–355) (Clore et al., 1994, 1995), and
the C-terminal negative regulatory domain (residues
360–393) (Ahn and Prives, 2001). It exists in a dimer-
tetramer equilibrium under physiological conditions
(Weinberg et al., 2004b). Two domains of p53 are in-
volved in DNA binding: the core domain has sequence-
specific binding to promoters of p53’s target genes,
and the C-terminal domain (CTD) binds to nonspecific
sequences in DNA (Jayaraman and Prives, 1999). p53*Correspondence: arf25@cam.ac.uk
2 Present address: Department of Organic Chemistry, the Hebrew
University of Jerusalem, Givat Ram, Jerusalem 91904, Israel.
3 These authors contributed equally to this work.undergoes posttranslational phosphorylation and acet-
ylation at several residues, as a regulatory mechanism
(Brooks and Gu, 2003).
The C-terminal domain regulates the sequence-spe-
cific DNA binding activity of the core domain (Ahn and
Prives, 2001; Hupp et al., 1992). When the CTD is un-
modified, it inhibits the binding of DNA to the core do-
main (Espinosa and Emerson, 2001). Phosphorylation
of S392 of the CTD activates the sequence-specific
DNA binding of p53 (Anderson et al., 1997; Bayle et al.,
1995; Hupp and Lane, 1994; Hupp et al., 1992, 1995).
CTD is acetylated by the histone acetyltransferase
p300/CBP at lysines 372, 373, 381, and 382, in re-
sponse to various cellular stress signals (Ito et al., 2001;
Liu et al., 1999; Prives and Manley, 2001; Sakaguchi et
al., 1998). Acetylation enhances the sequence-specific
DNA binding of the core domain in vitro (Gu and
Roeder, 1997).
The importance of acetylation is somewhat contro-
versial. Espinosa and Emerson (2001) showed that
while acetylation of p53 CTD can enhance its binding to
short DNA elements containing its sequence-specific
binding site in the p21 promoter, it had no effect on
binding to longer DNA fragments containing the same
promoter or when the DNA is packaged in the chroma-
tin. Moreover, they found that p53 that is mutated in
the p300/CBP target lysine residues still has the same
transactivation level as wild-type, suggesting that acet-
ylation is not important for DNA binding. Their conclu-
sion was that the role of p53 CTD acetylation is in co-
factor recruitment (Espinosa and Emerson, 2001).
Barlev et al. (2001) suggested that p53 CTD acetylation
is important for transcription, and its role is to facilitate
recruitment of transcriptional coactivators CBP and
TRAPP. Indeed, recent NMR studies showed that acety-
lation of K382 is crucial for binding of CBP by p53 CTD
(Mujtaba et al., 2004). Recently, Luo et al. challenged
the findings of Espinosa and Emerson, and showed
that full acetylation of p53 can dramatically increase its
sequence-specific DNA binding to short and long DNA
fragments (Luo et al., 2004). The p300/CBP target lysine
residues within p53 CTD are also ubiquitinated by
MDM2, and their acetylation inhibits this ubiquitination,
suggesting an additional regulatory role for p53 CTD
acetylation (Li et al., 2002; Nakamura et al., 2000). The
large number of sometimes apparently conflicting ob-
servations is most probably caused by the complexity
of the p53 activation pathway and different assays and
conditions employed.
Here, we studied the interaction of CTD with DNA
using the simplest model possible, isolated C-terminal
peptides and pure DNA, in order to formulate the un-
derlying principles of the interaction. The effect of
chemical modification of the CTD on binding to DNA
may be realistically studied using peptides as models
in vitro. The C-terminal domain of a dimeric construct
of p53 is unstructured in solution and is not affected by
the core domain (Ayed et al., 2001). The same is true
for tetrameric constructs (Weinberg et al., 2004a; un-
published data). We have identified by NMR studies the
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630residues in the CTD that bind to DNA, which include m
tK373, K381, and K382 (Weinberg et al., 2004a). We now
synthesize fluorescein-labeled p53 CTD peptides bear- e
uing specific single and multiple acetylations at the
p300/CBP target lysine residues, and a peptide phos- a
iphorylated at S392, to quantify accurately the effects
of modifications on the nonspecific DNA binding of p53
CTD. For tight binding, we used conventional measure-
ments using fluorescence anisotropy. To measure
weaker binding on acetylation, we have developed a
quantitative analytical ultracentrifuge-based method to
assay the binding of these peptides to DNA. Our data
showed that phosphorylation of S392 did not affect
binding of p53 CTD to DNA, while acetylation of K372,
K373, K381, and K382 inhibits its nonspecific DNA
binding in a mainly electrostatic manner.
Results
We synthesized a series of fluorescein-labeled pep-
tides derived from p53 CTD (residues 367–393), listed
in Table 1. The peptides had various combinations of
mono-, di-, tri-, and tetraacetylations at lysine residues
372, 373, 381, and 382, which are known to be acet-
ylated in vivo by p300/CBP (Gu and Roeder, 1997).
Phosphorylation of S392 in p53 CTD is a naturally oc-
curring posttranslational modification that was sug-
gested to stabilize the tetramer form of p53 (Sakaguchi
et al., 1997a). We synthesized a peptide with a phos-
phoserine at position 392, to test a possible effect of
S392 phosphorylation on DNA binding. We measured
binding of the peptides to sheared herring sperm DNA,
which represents a long nonspecific DNA sequence, at
various ionic strengths. To be able to measure the pep-
tide-DNA interactions accurately at high ionic strength,
we developed a convenient and general method to
Fquantitatively measure protein-peptide, DNA-peptide,
Cand protein-DNA interactions by analytical ultracentrif-
(ugation (AUC).
p
c
cQuantitative Analysis of Molecular Interactions
(by Analytical Ultracentrifugation
cThe principle of the AUC method described herein is
e
the use of fluorescein-labeled peptides, which enabled o
us to monitor the sedimentation profile of the peptide w
citself, both as a free peptide and in complex. TheTable 1. Peptides Derived from the C-Terminal Domain of p53 (Residues 367-393) Used in the Current Study
Peptide Sequence
Wild-type FL- SHLKSKKGQSTSRHKKLMFKTEGPDSD
K372Ac FL- SHLKSK(Ac)KGQSTSRHKKLMFKTEGPDSD
K373Ac FL- SHLKSKK(Ac)GQSTSRHKKLMFKTEGPDSD
K381Ac FL- SHLKSKKGQSTSRHK(Ac)KLMFKTEGPDSD
K382Ac FL- SHLKSKKGQSTSRHKK(Ac)LMFKTEGPDSD
K372/373Ac FL- SHLKSK(Ac)K(Ac)GQSTSRHKKLMFKTEGPDSD
K381/382Ac FL- SHLKSKKGQSTSRHK(Ac)K(Ac)LMFKTEGPDSD
K372/373/381Ac FL- SHLKSK(Ac)K(Ac)GQSTSRHK(Ac)KLMFKTEGPDSD
K372/373/381/382Ac FL-SHLKSK(Ac)K(Ac)GQSTSRHK(Ac)K(Ac)LMFKTEGPDSD
pS392 FL- SHLKSKKGQSTSRHKKLMFKTEGPDpSD
All peptides are derived from the C-terminal domain of p53, residues number 367-393. K(Ac), Lys (acetyl); pS, phosphoserine; FL, Fluorescein.
All peptides were amidated at the C terminus.ethod is presented in Figure 1. Samples containing
he labeled peptide in the concentration of 4–6 M and
xcess of either DNA or protein (in the current study we
sed sheared herring sperm DNA at 5 mg/ml or 26 M)
re loaded into the ultracentrifuge and allowed to equil-
brate at the selected speed. Each component presentigure 1. Sedimentation Profile of the Fluorescein-Labeled p53
-Terminal Peptide in the Presence of DNA
A) Absorbance data at 495 nm, monitoring the distribution of the
eptide. Solid line, experimental data and fit by the sum of two
omponents: free peptide (3 kDa, dashed line) and peptide-DNA
omplex (190 kDa, dotted line).
B) Interference data. Experimental data and a best fit to a single
omponent (M =187 kDa). Since DNA is present in the large mass
xcess, interference data reflect its distribution. The contributions
f individual components at the reference position are shown
ith symbols: square, free peptide; triangle, bound peptide; and
ircle, DNA.
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631in the sample (peptide, protein, or DNA and the com-
plex between them) would form a sedimentation profile
according to its mass (Figure 1). Both absorbance and
interference data sets are collected for each sample.
The absorbance data at 495 nm contains information
about the fluorescein-labeled species, which are the
free peptide and the peptide-DNA complex, as only the
peptide is labeled with fluorescein. Since the masses
of the free peptide and the complex are known, the ob-
served sedimentation profile could be fitted to a sum
of two theoretical functions representing these two
components (equation 1):
A(r) = Abaseline + Abottom1exp(M1b1) +
Abottom2exp(M2b2), (1)
where: β = ω2(r2 − rbottom2)(1 − Vpiρ)/(2RT); Abottomi =
iCbottomi; M is the molecular mass of molecule; Abottom
is absorbance at the bottom; r is the radial position;
rbottom is radius position of the bottom; Abaseline is the
absorbance of the buffer; ω is angular rotational speed
(rad/sec); R is the gas constant; T is absolute temper-
ature; Vp is partial specific volume of the protein (ml/g);
ρ is solvent density (g/ml);  is extinction coefficient of
the molecule; and Cbottom is its concentration at the
bottom. The relative contributions of the two compo-
nents to the sedimentation curve could be deconvo-
luted (Figure 1A). The interference optics measures a
change in the refraction index of the sample, which is
proportional to the mass concentration of the solute. In
our experiments the DNA or protein was present in
large mass excess over the peptide and, therefore, the
interference data allowed us to measure the amount
and distribution of DNA or protein present (Figure 1B).
The absorbance and interference data provided us
with complementary data. The absorbance data gave
the concentration of the free peptide and the complex,
while the interference data provided the concentration
of the DNA or protein. Since we know the concentration
of each individual component of the binding equilib-
rium, and the binding reaction is at equilibrium in any
position within the cell, we could calculate the binding
constant from a simple equilibrium equation:
Kd = (Afree /Abound) × [P], (2)
where, Afree and Abound are the contributions of the free
and bound peptide as measured by the absorbance
data (Figure 1A) and [P] is the concentration of the pro-
tein or DNA as measured by the interference data (Fig-
ure 1B) at the reference position.
To speed up the experiments, we reduced the volume
of the samples by the factor of 2 to 50 L, correspond-
ingly reducing the time it takes to reach equilibrium
4-fold to approximately 3–6 hr. This improved the
throughput of the method and allowed us to study sam-
ples with limited long-term stability.
The error in the calculated Kd (Kd, equation 3) origi-
nates from the errors of
Kd = (([P]2/Abound2 )Afree2 + (Afree2 [P]2/Abound4 )
Abound2 + (Afree2 /Abound2 )[P]2)1/2, (3)
determination of amplitudes of individual components,where Afree, Abound and [P] denote the errors in the
measured values. [P] could be adjusted in the experi-
ments in order to provide easily detectable amounts
(>0.1 absorbance units) of both free and bound pep-
tide. The accuracy of determination of Afree and Abound
is further improved by a substantial difference in mass
of the free peptide and a complex. Additionally, be-
cause the label is monitored at its unique absorbance
band, there are no baseline shifts and this contributes
to the accuracy of deconvolution of the two compo-
nents. The typical error of Kd determination in our ex-
periments was of the order of 3%–15%.
Binding to Nonspecific DNA Depends
on Ionic Strength
At physiological ionic strength (I = 150 mM), p53 CTD
bound the DNA with Kd = 14 M. The binding was de-
pendent on the ionic strength (Figure 2), and became
weaker as the ionic strength increased, indicating an
electrostatic contribution to the binding. At I = 225 mM,
p53 CTD bound the DNA twice as weakly, with Kd = 29
M, while at I = 100 mM the binding was 2-fold
stronger, reaching 7 M.
Acetylation Weakens Binding
The effect of acetylation on the DNA binding of p53
CTD was studied at physiological ionic strength (I = 150
mM) using AUC (Figure 3). Acetylation weakened DNA
binding to p53 CTD, and the binding affinity was depen-
dent mainly on the number of acetylations rather than
on their position. Acetylation of each of the four natural
p300/CBP target lysines (372, 373, 381, and 382) re-
sulted in 2.4-fold weakened binding (Kd = 37–42 M
compared to 15 M for WT p53 CTD). The DNA binding
affinity of diacetylated p53 CTD peptides was weaker
by 2.2-fold on average compared with the monoacety-
lated p53 CTD peptides. Diacetylation at Lys372 and
Lys373 had a larger effect on binding than diacetylationFigure 2. Ionic Strength Dependence of Binding of Sheared Herring
Sperm DNA to Fluorescein-Labeled Wild-Type p53 C-Terminal Pep-
tide (367–393)
Log of the dissociation constant in M is plotted against log of the
ionic strength (in mM). Data was obtained using AUC, except for I =
100 mM, where it was obtained using fluorescence spectroscopy.
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Figure 3. Binding of Sheared Herring Sperm DNA to Fluorescein- a
Labeled p53 C-Terminal Peptides, at Ionic Strengths of 150 mM
aand 225 mM
The dissociation constants were determined using AUC. The pep-
Dtides with three and four acetylations (K372/373/381Ac and K372/
B373/381/382Ac, respectively) did not bind detectably the DNA un-
der both ionic strength conditions. t
2
s
mof Lys381 and Lys382. Three acetylations (at Lys 373,
t381, and 382) and four acetylations (at all four lysines
isimultaneously) completely abolished the DNA binding
dof p53 CTD.
Since the DNA binding of wild-type p53 CTD is highly
tdependent on the ionic strength, we tested the effect
Gof acetylation on DNA binding of p53 CTD at different
aionic strengths. Increasing the ionic strength to I = 225
qmM resulted in approximately 2-fold weaker binding af-
sfinity of the DNA to wild-type p53 CTD. The effect of
eacetylation was similar to that observed at I = 150 mM:
iDNA binding affinity of the monoacetylated p53 CTD
epeptides was 2-fold weaker compared to the wild-type,
oand the affinity of the diacetylated p53 CTD peptides
cwas on average 2.2-fold weaker compared to the
Kmonoacetylated peptides. Three and four acetylations
dcompletely abolished the DNA binding of p53 CTD.
pAgain, Lys372 acetylation had a slightly larger effect on
wDNA binding compared to other acetylations.
oAt low ionic strength (I = 20.5 mM, which is the ionic
strength of the buffer without added NaCl) (Figure 4),
as expected for an interaction that is highly dominated D
by electrostatic forces, binding at I = 20.5 mM was
much tighter, with dissociation constants at the nM A
orange compared to the M range observed at higher
ionic strengths. Since our AUC method is not suitable W
mfor the determination of such low Kds (see Discussion),
we used fluorescence spectroscopy to analyze the t
iDNA binding of the p53 CTD peptides at I = 20.5 mM.
Acetylation had a more dramatic effect on the binding c
Taffinity at I = 20.5 mM: DNA binding of the monoacety-
lated p53 CTD peptides was on average 4.5-fold e
tweaker than that of wild-type, and the DNA binding of
the diacetylated peptides was on average 4.7 times i
sweaker than that of the monoacetylated ones (Figure
4). At this low ionic strength, the binding of triacetylated s53 CTD peptide was just detectable, with Kd = 1.1 M,
ut no binding could be detected with the tetraacet-
lated p53 CTD.
hosphorylation of S392 Did Not Affect Binding
hosphorylation of S392 is another posttranslational
odification involved in p53 regulation, and was shown
o induce DNA binding by the core domain (Hupp et al.,
992). To test whether S392 phosphorylation regulates
53 by altering the DNA binding affinity of p53 CTD, we
ave synthesized a p53 CTD peptide phosphorylated
t S392 (pS392 p53 CTD, see Table 1) and tested its
inding to herring sperm DNA using AUC. The binding
ffinity of pS392 p53 CTD to the DNA was very similar
o that of the wild-type peptide both at I = 150 mM and
= 225 mM (Figure 3). Thus, phosphorylation of S392
oes not have the same role as acetylation of the CTD
ysine residues. It could potentially still alter the DNA
inding affinity of p53 core domain in an indirect mech-
nism by stabilizing its tetramer form (Sakaguchi et
l., 1997a).
NA Binding Induces Little Structure into p53 CTD
ased on our assignments of a tetrameric construct of
he tetramerization domain and CTD (Weinberg et al.,
004a), we have analyzed NOESY experiments for the
tructural consequences of DNA binding. These experi-
ents detect short-range (<5 Å) interatomic interac-
ions that determine secondary structure. Particularly,
nteractions between nonneighboring residues are in-
icative of the global fold of a protein.
We were able to detect only sequential NH-NH con-
acts in the following regions: S371–S378 and Phe385–
ly389 (Figure 5). This excludes the possibility that CTD
dopts a global fold. The difficulty in detection of se-
uential contacts is partly due to the limited chemical
hift dispersion in the proton dimension but also due to
xchange broadening of residues L383 and M384. We
mproved the quality of the spectra compared with
arlier (Weinberg et al., 2004a) by using a larger excess
f DNA to shift the equilibrium toward formation of the
omplex. This enabled us to record the spectra at 298
, further improving the data quality. Based on our
ata, the most likely interpretation is the adoption of a
artially helical structure in the above regions, which
ould coincide with results reported for the interaction
f S100B with CTD (Rustandi et al., 2000).
iscussion
UC as a Tool for Quantitative Studies
f Molecular Interactions
e have developed a rapid and convenient AUC
ethod for quantitative analysis of molecular interac-
ions. It is generally applicable to studying molecular
nteractions of small molecules, peptides, and oligonu-
leotides with proteins, DNA, or other large molecules.
he prerequisites are that there is a significant differ-
nce in mass between two interacting partners and that
he smaller ligand has a unique absorbance band that
s not overlapping that of the protein or the DNA (the
econd, heavier interacting partner). Owing to the sen-
itivity limits of the instrument, the concentration of the
Modulation of p53 DNA Binding by Acetylation
633Figure 4. Binding of Sheared Herring Sperm
DNA to Fluorescein-Labeled p53 C-Terminal
Peptides at Low Ionic Strength (I = 20.5 mM)
The binding constants were determined
using fluorescence spectroscopy. Sheared
herring sperm DNA was titrated into fluores-
cein-labeled p53 C-terminal peptides, and
the changes in total fluorescence were moni-
tored. Shown is the total fluorescence cor-
rected for dilution. The data were fit to a 1:1
binding model with a linear drift (see Experi-
mental Procedures). (A) Titration curves. (B)
Kd values obtained from fitting the data
in (A).fluorescein-labeled peptide has to be around 5 M.
This dictates that the method is applicable for interac-
tions with dissociation constants in the M to mM
range. The imminent introduction of fluorescence de-
tection into AUC instruments will increase the sensitiv-
ity by a further one to two orders of magnitude.
We have crosschecked the method with fluorescence
polarization measurements in other cases where bothmethods can be used at similar concentrations of rea-
gents and have found excellent agreement (Fernandez-
Fernandez et al., 2005; Friedler et al., 2005).
Effect of Acetylation on Binding of Nonspecific
DNA to CTD
Here, we clearly showed that DNA bound tightly to p53
CTD peptides and acetylation of certain lysine residues
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Spectrometer Frequency of 800 MHz Illustrating Sequential Short- D
Range Contacts in the Region K373–S378 p
Strips are taken at the indicated amide (HN) chemical shift position; t
solid lines indicate NHi-NHi+1 connectivities dispersed by their 15N 1
chemical shifts, whereas dashed lines correspond to the symme-
try-related i,i-1 connectivity. This might be indicative for a partial
chelical structure of this region. Note that for these residues the 1H
tchemical shift dispersion is only 0.29 ppm.
o
e
ireduces its affinity to DNA, and three or four acetyla-
wtions rendered binding nearly indetectable. The data
bare consistent with our recent NMR studies that
Cshowed that lysines 373, 381, and 382 are directly in-
ivolved in DNA binding (Weinberg et al., 2004a). Mono-
acetylation weakened DNA binding at physiological
ionic strength 2- to 3-fold, diacetylations resulted in fur- B
Tther 2- to 3-fold decrease in the affinity, and tri- and
tetraacetylations rendered DNA binding undetectable. l
iPhosphorylation at S392 did not affect DNA binding.
How do these data translate into effects in vivo? The T
aabsolute values of Kd in vitro will differ from those
in vivo, but the relative order is important. Small 30 l
bbase pair fragments of DNA bind to the CTD in tetra-
meric constructs of p53 with a dissociation constants l
iof w8 M at an ionic strength of 225 mM (Weinberg
et al., 2004a), somewhat more tightly than the 29 M c
tmeasured for monomers here. But, a longer construct
of 300 base pairs (sheared herring sperm DNA) binds t
pfar more tightly: a 200 nM solution nearly completely
competes off (>90%) 10 nM mdm2 recognition element a
dof DNA that has a dissociation constant of 7 nM from
the core domain in the tetrameric construct (Weinberg t
tet al., 2004a). From this, we calculate that the longer
construct has a dissociation constant of < 20 nM. The o
Otight binding is because the 600 base pair fragment can
bind to more than one site in a tetrameric construct. a
Thus, long exposed tracts of nonspecific DNA may bind
tetrameric CTD sufficiently tightly to be of importance. t
bThe effects of acetylation were significant in weaken-
ing the binding to just individual CTDs. These effects k
ewill be magnified if the nonspecific DNA can bind to
more than one CTD in a multimeric complex. If, for ex- D
Dample, the DNA wraps itself around four subunits, the
overall binding will be much tighter because of the syn- p
cergy, and the relative effects on binding specificity will
increase to the power of 4. If the DNA is wrapped pround two sites in a dimer, then discrimination will be
aised by the power of 2. Whatever happens, acetyla-
ion greatly decreases the binding of nonspecific DNA
o the CTD of p53.
Our observation that phosphorylation of S392 has no
ffect on the DNA binding of p53 CTD is, again, in
greement with the NMR data, which shows no involve-
ent of this residue in DNA binding. This leaves open
he question of how phosphorylation activates p53
Hupp et al., 1992). One possibility is that S376 and
378, which are in the middle of the DNA binding
tretch, are also phosphorylated in their experiments.
upp et al. showed that phosphorylation was located
n the CTD, but the stoicheometry was up to 1.4:1, indi-
ating that more than one site was phosphorylated.
his explanation is supported by observation that mu-
ations of S389 in murine p53 do not affect its specific
NA binding (Rolley and Milner, 1994). Alternative ex-
lanations could be that phosphorylated S392 affects
he oligomerization state of p53 (Sakaguchi et al.,
997b) or recruits some other protein factor.
The fact the CTD is unstructured and its relaxation
haracteristics are that of the small protein indicate
hat it is not involved in interactions with other domains
f p53 in the unmodified form that tie it down (Weinberg
t al., 2004a). NMR experiments showed that the bind-
ng of DNA did not cause the domain to fold, but there
ere hints that the region around the lysine residues
ecame helical. This suggests that binding of DNA to
TD is unlikely to cause global conformational change
n the molecule of p53.
iological Implications
he question of whether acetylation has a role in regu-
ating the DNA binding of p53 is the subject of an ongo-
ng debate (Luo et al., 2004; Prives and Manley, 2001).
he very minimum conclusion we can draw is that CTD
cetylated on the relevant lysine residues is highly un-
ikely to bind to DNA. Next, the unacetylated CTD could
ind tightly enough to be important in regulation. If the
atter is true, then acetylation of the CTD removes the
nhibition, and enables the core domain to bind its spe-
ific DNA (Gu and Roeder, 1997). There may be an “in-
egration model” for regulation of p53: as the number of
he acetylations seem to matter rather that their exact
osition in the CTD, it is possible that the CTD acts as
n “integration device,” receiving the signal from the
ifferent upstream activators of p53 and combining
hem until a threshold for activation is passed. Acetyla-
ions are the markers for this threshold, e.g., any two
r any three acetylations would trigger the response.
ur data are consistent with a progressive change in
ffinity for DNA on increasing acetylation.
An important role of acetylation in p53 CTD was iden-
ified for other binding events of CTD, including protein
inding, cofactor recruitment (Barlev et al., 2001; Chui-
ov et al., 2004), and inhibition of their ubiquitination (Li
t al., 2002; Nakamura et al., 2000). More intriguingly,
ornan et al. (2003) found that presence of specific
NA increased acetylation of CTD by p300, and pro-
osed that acetylation is a post DNA binding event. Re-
ently, CTD was implicated in involvement in sliding of
53 along DNA and therefore being a positive rather
Modulation of p53 DNA Binding by Acetylation
635than negative regulator of p53 (McKinney et al., 2004).
Our data cast no light on these mechanisms.
Experimental Procedures
Materials
Peptides were synthesized on a Pioneer peptide synthesizer (Ap-
plied Biosystems) using standard Fmoc chemistry. Acetylated ly-
sine was incorporated into the peptides during SPPS using Fmoc-
Lys(Ac)-OH (NOVAbiochem). Phosphoserine was incorporated into
the peptide during SPPS using Fmoc-Ser (PO(Obzl)OH)-OH (NO-
VAbiochem). The peptides were labeled with fluorescein at the N
terminus on the Pioneer peptide synthesizer using 4-fold excess of
fluorescein-OSu (Molecular Probes) and 4-fold excess of hydroxy-
benzotriazole (HoBt). All other amino acids were purchased from
NOVAbiochem. The peptides were purified on a waters HPLC using
a reverse-phase C8 semipreparative column (Vydac) as described
(Friedler et al., 2002). Sheared herring sperm DNA was obtained
from Roche (Mannheim, Germany). The average molecular weight
of the DNA was measured by analytical centrifugation to be ap-
proximately 190 kDa, which corresponds to a 280 bp long piece
of DNA.
Analytical Ultracentrifugation
The equilibrium sedimentation experiments were performed on a
Beckman XL-I ultracentrifuge using Ti-60 rotor and 6-sector cells
at speeds of 6000 and 8000 rpm. All experiments were done at
10°C. Sample volume was 50 L. Samples were considered to be
at equilibrium as was judged by comparing several scans at each
speed. Buffer conditions were 50 mM HEPES and 5 mM DTT (pH
7.2). The ionic strength of the buffer was adjusted to the desired
total ionic strength (usually 150 or 225 mM) with a stock solution
of 3 M NaCl in the same buffer. Data were processed and analyzed
using UltraSpin software (http://www.mrc-cpe.cam.ac.uk) using the
method described in the Results.
Fluorescence Spectrostropy
Fluorescence titrations were performed using a Perkin-Elmer LS-
55 spectrofluorimeter equipped with Hamilton Microlab 500 titrator
and controlled by laboratory software, according to the procedure
described (Friedler et al., 2002). The fluorescein-labeled p53 CTD
peptide was dissolved in 50 mM Hepes buffer (pH 7.2) and 5 mM
DTT at the desired ionic strength to a final concentration of 0.1 M.
1 ml of the peptide solution was placed in a cuvette, and herring
sperm DNA (240 l, 2 mg/ml) was titrated into the peptide in 40
steps of 6 l. The total fluorescence was measured after each addi-
tion. The excitation wavelength was 480 nm (bandwidth 12 nm) and
the emission wavelength was 525 nm (bandwidth 12 nm). Data
were fit to a simple 1:1 equilibrium model according to the equa-
tion: F = F0 + (F*[P]/([P]+Kd)), where: F is the measured fluores-
cence emission, F is amplitude of the fluorescence change from
the initial value (peptide only) to the final value (peptide in com-
plex), [P] is the DNA concentration, F0 is the starting fluorescence
value, corresponding to the free peptide, and Kd is the dissociation
constant for the complex. In some cases, a linear drift term was
added to the above equation to account for nonspecific interac-
tions.
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